Show simple item record

dc.contributor.authorDuvenhage, Janie
dc.contributor.authorZeevaart, Jan Rijn
dc.contributor.authorEbenhan, Thomas
dc.contributor.authorGarny, Seike
dc.contributor.authorHernández González, Ignacio
dc.date.accessioned2019-06-04T07:06:19Z
dc.date.available2019-06-04T07:06:19Z
dc.date.issued2019
dc.identifier.citationDuvenhage, J. et al. 2019. Molecular imaging of a zirconium-89 labeled antibody targeting Plasmodium falciparum–infected human erythrocytes. Molecular imaging and biology, (In press). [https://doi.org/10.1007/s11307-019-01360-3]en_US
dc.identifier.issn1536-1632
dc.identifier.issn1860-2002 (Online)
dc.identifier.urihttp://hdl.handle.net/10394/32494
dc.identifier.urihttps://link.springer.com/article/10.1007/s11307-019-01360-3
dc.identifier.urihttps://doi.org/10.1007/s11307-019-01360-3
dc.description.abstractPurpose Nuclear imaging is an important preclinical research tool to study infectious diseases in vivo and could be extended to investigate complex aspects of malaria infections. As such, we report for the first time successful radiolabeling of a novel antibody specific to Plasmodium-infected erythrocytes (IIIB6), its in vitro assessment and molecular imaging in nude mice. Procedures In vitro confocal microscopy was used to determine the stage-specificity of Plasmodium-infected erythrocytes recognised by IIIB6. To enable micro-positron emission tomography (PET)/X-ray computed tomography (CT) imaging, IIIB6 was conjugated to Bz-DFO-NCS and subsequently radiolabeled with zirconium-89. Healthy nude mice were injected with [89Zr]IIIB6, and pharmacokinetics and organ uptake were monitored over 24 h. This was followed by post-mortem animal dissection to determine the biodistribution of [89Zr]IIIB6. Results IIIB6 recognised all the relevant stages of Plasmodium falciparum-infected erythrocytes (trophozoites, schizonts and gametocytes) that are responsible for severe malaria pathology. [89Zr]IIIB6-radiolabeling yields were efficient at 84–89 %. Blood pool imaging analysis indicated a pharmacological half-life of 9.6 ± 2.5 h for [89Zr]IIIB6. The highest standard uptake values were determined at 2–6 h in the liver followed by the spleen, kidneys, heart, stomach and lung, respectively. Minimal activity was present in muscle and bone tissues. Conclusion In vitro characterization of IIIB6 and pharmacokinetic characterization of [89Zr]IIIB6 revealed that this antibody has potential for future use in Plasmodium-infected mouse models to study malaria in a preclinical in vivo setting with PET/CT imagingen_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.subjectPlasmodium falciparumen_US
dc.subjectMicro-PET/CT imagingen_US
dc.subject[89Zr]IIIB6en_US
dc.subjectNimotuzumaben_US
dc.subjectZirconium-89en_US
dc.titleMolecular imaging of a zirconium-89 labeled antibody targeting Plasmodium falciparum–infected human erythrocytesen_US
dc.typeArticleen_US
dc.contributor.researchID16951484 - Zeevaart, Jan Rijn


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record